A Randomized, Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of SHR-1905 Injection in Patients With Moderate to Severe Atopic Dermatitis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• The subjects have voluntarily signed the informed consent form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study.
• At the time of signing the informed consent, the subjects are ≥ 18 years old and ≤ 75 years old, male or female.
• Have atopic dermatitis at screening.
Locations
Other Locations
China
Dermatology Hospital of Southern Medical University
RECRUITING
Guangzhou
Contact Information
Primary
Ran Li
ran.li@hengrui.com
+86-0518-82342973
Time Frame
Start Date: 2025-11-07
Estimated Completion Date: 2027-02
Participants
Target number of participants: 70
Treatments
Experimental: SHR-1905 Injection Group - Dose 1
Dose 1.
Placebo_comparator: SHR-1905 Injection Placebo Group
Experimental: SHR-1905 Injection Group - Dose 2
Dose 2.
Related Therapeutic Areas
Sponsors
Leads: Guangdong Hengrui Pharmaceutical Co., Ltd